Sugi Predict

Sugi Predict / Compounds / SCHEMBL3078960

SCHEMBL3078960

SCHEMBL3078960

CCN(C(=O)C(Cc1cnn(Cc2ccccc2)c1)C(=O)NS(=O)(=O)/C=C/c1ccccc1)c1ccc(F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.39
▸ HDAC2 Q92769 2/20 0.36
▸ PKM P14618 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ NOS3 P29474 1/20 0.34
▸ NOS1 P29475 1/20 0.34
▸ NOS2 P35228 1/20 0.34
▸ TCF4 P15884 1/20 0.33
▸ CTNNB1 P35222 1/20 0.33
▸ GRIN1 Q05586 1/20 0.33
▸ GRIN2B Q13224 1/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ GBA1 P04062 1/20 0.32
▸ HTT P42858 2/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ F2 P00734 1/20 0.32
▸ OPRK1 P41145 1/20 0.32
▸ SCD O00767 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3078964 1.00 LMNA (0.39) LMNAHDAC2PKMKMT2ANOS3
SCHEMBL3090767 0.97 LMNA (0.39) LMNAHDAC2PKMKMT2ANOS3
SCHEMBL3090762 0.97 LMNA (0.39) LMNAHDAC2PKMKMT2ANOS3
SCHEMBL3097463 0.97 LMNA (0.40) LMNAHDAC2PKMKMT2ANOS3
SCHEMBL3097471 0.97 LMNA (0.40) LMNAHDAC2PKMKMT2ANOS3
SCHEMBL3092559 0.94 HDAC2 (0.35) LMNAHDAC2HTTALDH1A1F2
SCHEMBL3092554 0.94 HDAC2 (0.35) LMNAHDAC2HTTALDH1A1F2
SCHEMBL3469656 0.94 F2 (0.35) LMNAHDAC2PKMKMT2ANOS3
SCHEMBL3469653 0.94 F2 (0.35) LMNAHDAC2PKMKMT2ANOS3
Hydrochloric Acid SCHEMBL3093239 0.94 F2 (0.34) LMNAHDAC2PKMKMT2ANOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 — — EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 — — EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 — — US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 — — US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 LMNA 3803/4885HDAC2 1497/4885PKM 1468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.